Susan Swindells1, Ritesh Ramchandani1, Amita Gupta1, Constance A Benson1, Jorge Leon-Cruz1, Noluthando Mwelase1, Marc A Jean Juste1, Javier R Lama1, Javier Valencia1, Ayotunde Omoz-Oarhe1, Khuanchai Supparatpinyo1, Gaerolwe Masheto1, Lerato Mohapi1, Rodrigo O da Silva Escada1, Sajeeda Mawlana1, Peter Banda1, Patrice Severe1, James Hakim1, Cecilia Kanyama1, Deborah Langat1, Laura Moran1, Janet Andersen1, Courtney V Fletcher1, Eric Nuermberger1, Richard E Chaisson1. 1. From the University of Nebraska Medical Center, Omaha (S.S., C.V.F.); Harvard T.H. Chan School of Public Health, Boston (R.R., J.L.-C., J.A.); Johns Hopkins University School of Medicine, Baltimore (A.G., E.N., R.E.C.), and Social and Scientific Systems, Silver Spring (L. Moran) - both in Maryland; University of California, San Diego, School of Medicine, La Jolla (C.A.B.); GHESKIO, Port-au-Prince, Haiti (M.A.J.J., P.S.); Asociación Civil Impacta Salud y Educación, Lima, Peru (J.R.L., J.V.); Botswana-Harvard AIDS Partnership, Gaborone, Botswana (A.O.-O., G.M.); Chiang Mai University, Chiang Mai, Thailand (K.S.); Helen Joseph Hospital, Johannesburg (N.M.), Perinatal HIV Research Unit, Soweto (L. Mohapi), and the University of Kwa-Zulu Natal, Durban (S.M.) - all in South Africa; Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro (R.O.S.E.); Johns Hopkins-Blantyre Clinical Trials Unit, Blantyre (P.B.), and the University of North Carolina-Lilongwe Clinical Research Site, Lilongwe (C.K.) - both in Malawi; the University of Zimbabwe, Harare (J.H.); and Kenya Medical Research Institute-Walter Reed Clinical Research Site, Nairobi (D.L.).
Abstract
BACKGROUND: Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS: We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25. RESULTS: A total of 3000 patients were enrolled and followed for a median of 3.3 years. Of these patients, 54% were women; the median CD4+ count was 470 cells per cubic millimeter, and half the patients were receiving antiretroviral therapy. The primary end point was reported in 32 of 1488 patients (2%) in the 1-month group and in 33 of 1498 (2%) in the 9-month group, for an incidence rate of 0.65 per 100 person-years and 0.67 per 100 person-years, respectively (rate difference in the 1-month group, -0.02 per 100 person-years; upper limit of the 95% confidence interval, 0.30). Serious adverse events occurred in 6% of the patients in the 1-month group and in 7% of those in the 9-month group (P = 0.07). The percentage of treatment completion was significantly higher in the 1-month group than in the 9-month group (97% vs. 90%, P<0.001). CONCLUSIONS: A 1-month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infected patients. The percentage of patients who completed treatment was significantly higher in the 1-month group. (Funded by the National Institute of Allergy and Infectious Diseases; BRIEF TB/A5279 ClinicalTrials.gov number, NCT01404312.).
RCT Entities:
BACKGROUND:Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS: We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infectedpatients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25. RESULTS: A total of 3000 patients were enrolled and followed for a median of 3.3 years. Of these patients, 54% were women; the median CD4+ count was 470 cells per cubic millimeter, and half the patients were receiving antiretroviral therapy. The primary end point was reported in 32 of 1488 patients (2%) in the 1-month group and in 33 of 1498 (2%) in the 9-month group, for an incidence rate of 0.65 per 100 person-years and 0.67 per 100 person-years, respectively (rate difference in the 1-month group, -0.02 per 100 person-years; upper limit of the 95% confidence interval, 0.30). Serious adverse events occurred in 6% of the patients in the 1-month group and in 7% of those in the 9-month group (P = 0.07). The percentage of treatment completion was significantly higher in the 1-month group than in the 9-month group (97% vs. 90%, P<0.001). CONCLUSIONS: A 1-month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventing tuberculosis in HIV-infectedpatients. The percentage of patients who completed treatment was significantly higher in the 1-month group. (Funded by the National Institute of Allergy and Infectious Diseases; BRIEF TB/A5279 ClinicalTrials.gov number, NCT01404312.).
Authors: Haileyesus Getahun; Reuben Granich; Delphine Sculier; Christian Gunneberg; Leopold Blanc; Paul Nunn; Mario Raviglione Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: Lois J Eldred; Gavin Churchyard; Betina Durovni; Peter Godfrey-Faussett; Alison D Grant; Haileyesus Getahun; Richard E Chaisson Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: F Gordin; R E Chaisson; J P Matts; C Miller; M de Lourdes Garcia; R Hafner; J L Valdespino; J Coberly; M Schechter; A J Klukowicz; M A Barry; R J O'Brien Journal: JAMA Date: 2000-03-15 Impact factor: 56.272
Authors: Tianyu Zhang; Si-Yang Li; Kathy N Williams; Koen Andries; Eric L Nuermberger Journal: Am J Respir Crit Care Med Date: 2011-06-09 Impact factor: 21.405
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Mauro Schechter; Roberto Zajdenverg; Gisely Falco; Grace Link Barnes; José Cláudio Faulhaber; Jacqueline S Coberly; Richard D Moore; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-02-10 Impact factor: 21.405
Authors: Tianyu Zhang; Ming Zhang; Ian M Rosenthal; Jacques H Grosset; Eric L Nuermberger Journal: Am J Respir Crit Care Med Date: 2009-09-03 Impact factor: 21.405
Authors: Eleanor S Click; Ekaterina V Kurbatova; Heather Alexander; Tracy L Dalton; Michael P Chen; James E Posey; Julia Ershova; J Peter Cegielski Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079